KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Johnson & Johnson (JNJ) EBITDA (2016 - 2025)

Historic EBITDA for Johnson & Johnson (JNJ) over the last 17 years, with Q4 2025 value amounting to $5.5 billion.

  • Johnson & Johnson's EBITDA rose 5301.47% to $5.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $25.4 billion, marking a year-over-year increase of 2071.38%. This contributed to the annual value of $25.4 billion for FY2025, which is 2071.38% up from last year.
  • Per Johnson & Johnson's latest filing, its EBITDA stood at $5.5 billion for Q4 2025, which was up 5301.47% from $7.0 billion recorded in Q3 2025.
  • Johnson & Johnson's EBITDA's 5-year high stood at $7.0 billion during Q3 2025, with a 5-year trough of $3.6 billion in Q4 2024.
  • For the 5-year period, Johnson & Johnson's EBITDA averaged around $5.6 billion, with its median value being $5.8 billion (2023).
  • Its EBITDA has fluctuated over the past 5 years, first surged by 5520.52% in 2021, then tumbled by 3809.52% in 2023.
  • Johnson & Johnson's EBITDA (Quarter) stood at $6.6 billion in 2021, then fell by 19.79% to $5.3 billion in 2022, then decreased by 19.78% to $4.3 billion in 2023, then decreased by 15.34% to $3.6 billion in 2024, then soared by 53.01% to $5.5 billion in 2025.
  • Its EBITDA stands at $5.5 billion for Q4 2025, versus $7.0 billion for Q3 2025 and $6.6 billion for Q2 2025.